Key result
Low-dose DOACs linked to ~85% less CRNMB vs full-dose in cancer without higher VTE recurrence.
Why the study?
This study examined the effectiveness, safety, and utilization of low-dose DOACs for extended VTE prevention in a real-world cohort, with dedicated analysis of cancer patients.
Does extended low-dose DOAC therapy reduce bleeding without increasing VTE recurrence in patients with VTE (with and without cancer) compared to full-dose DOAC therapy?
Observational (n=2,737)
No
Does extended low-dose DOAC therapy reduce bleeding without increasing VTE recurrence in patients with VTE (with and without cancer) compared to full-dose DOAC therapy?
Extended low-dose DOAC therapy in VTE patients, particularly those with cancer, maintains low VTE recurrence rates while significantly decreasing bleeding complications compared to full-dose therapy.
Answers are grounded in this paper and cite their sources.
Supports exploring low-dose DOACs to cut bleeding in cancer VTE; hypothesis-generating and should not yet change practice.
Abstract Background Low-dose direct oral anticoagulants (DOACs) have been studied in randomized controlled trials for extended prevention of venous thromboembolism (VTE) after 6 months at therapeutic doses. Objectives This study examined the effectiveness, safety, and utilization of low-dose DOACs in a real-world cohort with dedicated analysis of cancer patients. Methods Consecutive patients enrolled in the Mayo Clinic VTE Registry from March 1, 2013, to December 31, 2022, were followed prospectively for VTE recurrence, major bleeding (MB), and clinically relevant non-MB (CRNMB). Patients with events during the first 3 months were excluded. After anticoagulation for 3 months with either rivaroxaban or apixaban, characteristics and outcomes of patients continuing anticoagulation were evaluated by Cox regression and a nested case-control study. Results In total, 466 patients (71% apixaban and 29% rivaroxaban) were identified on low-dose DOACs and 2273 in the full-dose group. Demographics between groups were mostly similar. Patients with active cancer as a provoking factor were less common in the overall low-dose DOAC group. In Cox regression analysis, VTE recurrence was not different between any groups. In noncancer patients, CRNMB but not MB was decreased in the low-dose group (hazard ratio [HR], 4.97; P < .001). In patients with cancer, low-dose DOACs were protective for MB (HR, 4.48; P = .001) and CRNMB (HR, 6.81; P < .001). Bleeding outcomes were the same in nested case-control analysis as well. Conclusion Dose reduction maintains low recurrence rates but also decreases bleeding, with the most pronounced effect in the cancer population.
No takes yet. Share an insight, caveat, or question.
Vlazny et al. (2025) conducted an observational in Venous thromboembolism (n=2,737). Low-dose direct oral anticoagulants vs. Full-dose direct oral anticoagulants was evaluated on Clinically relevant non-major bleeding (CRNMB) in cancer patients (HR 6.81, 95% CI 3.48-13.35, p=<0.001). In patients with cancer, low-dose direct oral anticoagulants reduced the risk of clinically relevant non-major bleeding compared to full-dose therapy, without increasing VTE recurrence.
Synapse has enriched 10 related papers. Consider them for comparative context: